Arterys Receives Seventh US FDA Clearance

Raises $28 Million to Accelerate the Delivery of Medical AI to Practices Around the World

Arterys, a leading global medical imaging platform to deliver clinical AI products over the internet, just received its seventh USA FDA clearance and announced its latest round of funding — a $28 million Series C investment from a syndicate led by Benslie Investment Group and Temasek Holdings, with participation by Fosun, Revelation Partners, Emergent Medical Partners, and Varian Medical Systems.

Arterys said it will deploy this new round of financing to broaden the Arterys ecosystem, comprising a broad set of partners on the new Arterys Marketplace working together to deliver clinical applications built on the Arterys cloud-native viewer and platform. A particular focus will be to accelerate partners’ efforts to bring new clinical-grade AI applications to providers by extending its proprietary technology platform to application partners thereby making it easier for clinicians to integrate AI into their workflows from a single interface.

“The current crisis has shown us the necessity of a different approach to providing healthcare, where technology and AI are crucial for future success. Arterys is committed to transforming the way AI is integrated into the medical workflow, a promise that is long due in the industry. We recently launched our cloud platform and marketplace that will consolidate the work of thousands of AI models to be readily available for use by healthcare institutions around the globe,” said Henry Weinstein, Managing Partner at Benslie International Ltd.

Arterys has appointed John Axerio-Cilies, co-founder, as the acting CEO. “We realize that we can’t transform the healthcare system alone,” says Axerio-Cilies. “No company can. And now, the same technology and strengths that we’ve leveraged to build our core products [Arterys Cardio AI and Arterys Lung AI] are now available to medical innovators at companies and universities around the world — they can benefit from regulatory support, channel partnerships, performance, security, and best-in-class hospital system integrations.”

SourceArterys

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.